GenScript and T-MAXIMUM partner for CAR-T cell therapy development
10 Aug 2023
Cell TherapyImmunotherapyGene Therapy
Preview
Source: Pharmaceutical Technology
The partnership will develop CAR-T cell therapy by leveraging GenScript’s CRISPR nucleic acid re-agents. Credit: Design_Cells / Shutterstock.com.
Preview
Source: Pharmaceutical Technology
Genscript Biotech has formed a strategic collaboration agreement with T-MAXIMUM Biotech to develop CAR-T cell therapy.
Leveraging GenScript’s CRISPR nucleic acid re-agents, the partnership will focus on developing T-MAXIMUM’s CAR-T cell therapy.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - CD19/BCMA Targeted CAR T-Cells GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - CAR-T Cell Multiple Myeloma GlobalData
View allCompanies IntelligenceGenscript Biotech CorpRAMP Inc.GenScript Corp.View all
GenScript research and development (R&D) and manufacturing vice-president Dr Li Hong stated: “Our R&D-to-GMP-level sgRNA will support their UCAR-T products for solid tumours. While CAR-T cell therapies have made remarkable strides in haematological tumours, addressing the unmet need for solid tumours remains crucial.”
T-MAXIMUM will receive a number of CRISPR re-agents from GenScript. These will support the development of T-MAXIMUM’s universal CAR-T products from discovery to commercialisation.
GenScript’s partnership with T-MAXIMUM will drive the latter’s strategic development plan, advancing products into Phase II clinical research and enabling market delivery up to 2027.
T-MAXIMUM is currently focused on the development of its universal CAR-T cell therapy product, MT027, to treat recurrent high-grade gliomas.
T-MAXIMUM CEO Dr Shang Xiaoyun stated: “Gene-editing reagents are crucial raw materials for the quality and efficacy of our products. We are confident that this collaboration will accelerate the regulatory processes in China and the US, expediting T-MAXIMUM’s first product pipeline to benefit patients in need as soon as possible.”
With business operations in more than 100 countries and regions across the world, GenScript offers life-science R&D and manufacturing services.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.